Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer
1. Median overall survival was 3.1 months greater in the nivolumab plus ipilimumab group. 2. Grade 3-4 treatment-related adverse events ...
Tag: ipilimumab
Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer
1. Progression-free survival was significantly greater in the nivolumab plus ipilimumab group compared to nivolumab alone. 2. Treatment-related adverse events ...
Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma
1. In this randomized controlled trial, two cycles of neoadjuvant ipilimumab plus nivolumab resulted in longer event-free survival than adjuvant ...
#VisualAbstract: Neoadjuvant Nivolumab and Ipilimumab Improve Outcomes in Resectable Stage III Melanoma
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Nivolumab plus ipilimumab does not improve survival in post-nephrectomy patients with renal cell carcinoma
1. Disease-free survival in the placebo group was 50.7 months and was never reached in the intervention group; however, there ...
#VisualAbstract: Tumor-infiltrating lymphocyte therapy compared to ipilimumab in advanced melanoma
1 .Tumor-infiltrating lymphocytes therapy shows improvements in PFS when compared to ipilimumab 2. All patients with tumor-infiltrating lymphocytes therapy had ...
Tumor-infiltrating lymphocyte therapy compared to ipilimumab in advanced melanoma
1 .Tumor-infiltrating lymphocytes therapy shows improvements in PFS when compared to ipilimumab 2. All patients with tumor-infiltrating lymphocytes therapy had ...
#VisualAbstract: Second-line immunosuppression associated with worse outcomes for immune-related adverse events in melanoma
1. Median overall survival was longer in patients receiving steroid-only treatment for adverse events associated with immune response. 2. Patients ...
#VisualAbstract: Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma
1. 4-year recurrence-free survival was significantly higher with nivolumab plus ipilimumab compared to placebo. 2. Overall survival was significantly higher ...
Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma
1. 4-year recurrence-free survival was significantly higher with nivolumab plus ipilimumab compared to placebo. 2. Overall survival was significantly higher ...